BBNX · Beta Bionics, Inc.

Track BBNX — free Ask ALVIS about BBNX

$15.81 -0.18 (-1.13%) At close · Jul 28

Market Cap

$704.07M

Shares

44.56M

Beta Bionics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Beta Bionics, Inc. (BBNX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts

· $20.44M −$18.11M '24 Q4 25-03-25 ▲36.4% $17.64M −$28.66M '25 Q1 25-05-06 ▲54.4% $23.24M −$16.87M '25 Q2 25-07-29 ▲63.1% $27.25M −$14.21M '25 Q3 25-10-28 ▲57.1% $32.12M −$13.47M '25 Q4 26-01-08 LATEST ▲56.6% $27.63M −$21.89M '26 Q1 26-04-21

Beta Bionics, Inc. Q1 FY2026 Earnings Call

Confident tone Revenue growth and new patient starts Gross margin improvement Full-year 2026 guidance raise

Audio Transcript Slides 8-K10-Q

Beta Bionics, Inc. Q4 FY2025 Earnings Call

Confident tone 2026 guidance and outlook Pharmacy channel strategy User growth and installed base

Audio Transcript Slides 8-K10-K

Beta Bionics, Inc. Q3 FY2025 Earnings Call

Confident tone iLet commercial momentum FDA 483 / MAUDE reports Innovation pipeline (Mint and bihormonal)

Audio Transcript Slides 8-K10-Q

Beta Bionics, Inc. Q2 FY2025 Earnings Call

Confident tone Pharmacy Channel Adoption iLet Product & Real-World Clinical Data Innovation Pipeline (Mint & Bihormonal)

Audio Transcript Slides 8-K10-Q

Beta Bionics, Inc. Q1 FY2025 Earnings Call

Confident tone Q1 financial outperformance and raised 2025 guidance iLet product differentiation and algorithm Gross margin dynamics and near-term headwinds

Audio Transcript Slides 8-K10-Q

Beta Bionics, Inc. Q4 FY2024 Earnings Call

Audio Transcript Slides 8-K10-K

Showing 1–6 of 6 earnings calls

Key facts CIK 1674632 CUSIP 08659B102 13F (30d) 24 filings 24 filers Visit website